ArcticZymes Technologies
1 investor is following this company
ArcticZymes Technologies is a biotechnology company. The company specializes in the research and development of pharmaceuticals for the treatment of immune diseases. The main focus is on the development of glucans, the development of immune-stimulating agents, and the analysis of enzymes. The vision is to test and develop the medicine and then pass these on in use for RNA and DNA processes. ArcticZymes Technologies previously went by the name Biotec Pharmacon and is headquartered in Tromsö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Oslo Børs
AZT
Daily low / high price
-
Market cap
-
Turnover
-
Volume
-
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Skandinaviska Enskilda Banken AB | 12.8 % | 12.8 % |
Skandinaviska Enskilda Banken AB 2 | 7.3 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
ArcticZymes Technologies ASA: Registration of share capital following exercise of options
ArcticZymes Technologies ASA: Increase of share capital related to exercise of options
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools